Latest News From Lumira Ventures

Results from ExactVu™ Micro-Ultrasound Studies Featured Prominently at the American Urological Association’s (AUA) 114th Annual Meeting in Chicago, IL

Jennifer Schram Exact Imaging, Portfolio News, Press Release

Micro-Ultrasound and its Significant Clinical Benefits are Featured at the Largest Prostate Cancer Conference in 2 Clinical Talks, 5 Oral Presentations and Clinical Posters and a Skills Symposium CHICAGO, IL — (May 3, 2019) Exact Imaging, the world’s leader in …

Opsens Q2 2019 Revenues Reach a Record Level

Jennifer Schram Opsens, Portfolio News, Press Release

QUEBEC CITY, April 11, 2019 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today reported its results for the second quarter of 2019. HIGHLIGHTS Consolidated revenues totaled $7.9M in the second quarter of 2019 compared with $5.4M in the corresponding period in 2018, an increase of $2.5M or …

Forbius’ AVID200, a Novel TGF-beta 1 & 3 Inhibitor, Cleared by Health Canada to Commence Phase 1 Clinical Trial in Solid Tumors

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

Expansion of ongoing AVID200 Phase 1 solid tumor trial to include patients at clinical sites in Canada AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the principal oncogenic TGF-beta isoforms Best-in-class efficacy and safety potential …

New Data Confirms Cardiac Dimensions’ Carillon® System Provides Acute Hemodynamic Efficacy in Patients with Functional Mitral Regurgitation

Jennifer Schram Cardiac Dimensions, Portfolio News, Press Release

MANNHEIM, Germany – April 26, 2019 — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments to address functional mitral regurgitation (FMR) in patients with heart failure (HF), presented new data confirming significant reduction in regurgitant volume …

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019 SOUTH SAN FRANCISCO, Calif., April 24, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical …

Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

Investigator-initiated trial to evaluate AVID200’s safety, anti-fibrotic activity, and ability to restore hematopoiesis in patients with myelofibrosis AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the principal drivers of fibrosis in myelofibrosis and other fibrotic …

Forbius Announces First Patient Dosed in Phase 2a Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

This trial evaluates the efficacy of AVID100 in TNBC patients with EGFR-overexpression 20% of TNBC patients highly overexpress EGFR; there is no approved targeted therapy AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development, targeting both wild-type …

Bardy Diagnostics™ Announces $35.5M in Series B Funding Round

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, April 16, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding, led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion …

Aurinia Pharmaceuticals Inc. Announces New CEO and Board Director and Appoints New Chairman of the Board

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer …